RxSight, Inc. (RXST)
Nasdaq · Ophthalmic Goods · Manufacturing · CIK 1111485 · fiscal year ends in Dec
Closing price $4.86 on 30 Oct 2026; 52-week range $4.51 to $13.09.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $121.1M
- Revenue growth
- -17.7%
- Net income, last twelve months
- -$46.9M
- Earnings per share
- -$1.13
- Gross margin
- 76.3%
- Operating margin
- -45.5%
- Net margin
- -38.8%
- Free cash flow
- -$27.2M
- Return on equity
- -17.8%
- Market value
- $201.9M
- Cash
- $13.4M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 41.6M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $134.5M | -$48.2M | -$38.9M | -$0.95 | -$19.3M | 10-K filed 25 Feb 2026 |
| FY2024 | 31 Dec 2024 | $139.9M | -$36.9M | -$27.5M | -$0.71 | -$22.4M | 10-K filed 25 Feb 2025 |
| FY2023 | 31 Dec 2023 | $89.1M | -$50.1M | -$48.6M | -$1.41 | -$46.4M | 10-K filed 28 Feb 2024 |
| FY2022 | 31 Dec 2022 | $49.0M | -$63.3M | -$66.8M | -$2.41 | -$61.2M | 10-K filed 6 Mar 2023 |
| FY2021 | 31 Dec 2021 | $22.6M | -$52.8M | -$48.7M | -$3.57 | -$46.6M | 10-K filed 8 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $27.2M | -$12.1M | -$0.29 |
| Q1 FY2026 | 31 Mar 2026 | $30.9M | -$15.9M | -$0.38 |
| Q4 FY2025 | 31 Dec 2025 | $32.6M | -$9.2M | -$0.22 |
| Q3 FY2025 | 30 Sep 2025 | $30.3M | -$9.8M | -$0.24 |
| Q2 FY2025 | 30 Jun 2025 | $33.6M | -$11.8M | -$0.29 |
| Q1 FY2025 | 31 Mar 2025 | $37.9M | -$8.2M | -$0.20 |
| Q4 FY2024 | 31 Dec 2024 | $40.2M | -$5.9M | -$0.15 |
| Q3 FY2024 | 30 Sep 2024 | $35.3M | -$6.3M | -$0.16 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| LAL | $108.1M | 80.4% |
| L D D | $20.7M | 15.4% |
| Service Warranty, Service Contracts, And Accessories | $5.7M | 4.3% |
Company events
The newest 8-K filings of 50 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 15 Jul 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 6 Jul 2026 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 6 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 16 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 6 May 2026 | 8-K | Results | 2.02, 9.01 |
| 19 Mar 2026 | 8-K/A | Leadership change | 5.02 |
| 25 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jan 2026 | 8-K | Results, Leadership change, Investor update | 2.02, 5.02, 7.01, 9.01 |
| 23 Dec 2025 | 8-K | Leadership change, Investor update | 5.02, 7.01 |
| 22 Dec 2025 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 19 Dec 2025 | 8-K | Leadership change | 5.02 |
Every filing
The newest filings with the SEC of 138 held.
| Filed | Form | Period |
|---|---|---|
| 8 Sep 2026 | SC TO-I/A | – |
| 25 Aug 2026 | SC TO-I/A | – |
| 10 Aug 2026 | SC TO-I | – |
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 5 Aug 2026 | 8-K | 5 Aug 2026 |
| 23 Jul 2026 | S-8 | – |
| 15 Jul 2026 | 8-K | 13 Jul 2026 |
| 6 Jul 2026 | 8-K | 30 Jun 2026 |
| 6 Jul 2026 | 8-K | 6 Jul 2026 |
| 16 Jun 2026 | 8-K | 16 Jun 2026 |
| 29 May 2026 | SD | – |
| 6 May 2026 | 10-Q | 31 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 2 Sep 2026 | Kurtz Ronald M Md, Chief Medical Officer | Sale outside a trading plan | 5,100 | $6.96 | $35.5K | 71,775 | 2 Sep 2026 |
| 2 Sep 2026 | Wilterding Mark, Chief Financial Officer | Sale outside a trading plan | 7,765 | $6.96 | $54.0K | 25,049 | 2 Sep 2026 |
| 2 Sep 2026 | Goldshleger Ilya, Chief Operating Officer | Sale outside a trading plan | 2,041 | $6.96 | $14.2K | 81,509 | 2 Sep 2026 |
| 2 Sep 2026 | Weinberg Eric, See remarks | Sale outside a trading plan | 2,041 | $6.96 | $14.2K | 200,348 | 2 Sep 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 2 Sep 2026 | Goldshleger Ilya, Officer | 2,041 | $14.2K | 2 Sep 2026 |
| 2 Sep 2026 | Weinberg Eric, Officer | 2,041 | $14.2K | 2 Sep 2026 |
| 2 Sep 2026 | Kurtz Ronald M MD, Officer | 5,100 | $35.5K | 2 Sep 2026 |
| 2 Sep 2026 | Wilterding Mark, Officer | 7,765 | $54.0K | 2 Sep 2026 |
| 18 Aug 2026 | RAYMOND W COHEN, Former Director | 11,890 | $75.7K | 18 Aug 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock Portfolio Management LLC | 13G amended | 8.4% | 3.5M |
| 27 Oct 2026 | BlackRock, Inc. | 13G amended | 6.9% | 2.9M |
| 19 Aug 2026 | Point72 Asset Management, L.P. | 13G | 6% | 2.5M |
| 4 Aug 2026 | Millennium Management LLC | 13G amended | 7.3% | 3.0M |
| 17 Jul 2026 | BlackRock Portfolio Management LLC | 13G | 7.2% | 3.0M |
| 13 May 2026 | Artisan Partners Asset Management Inc. | 13G amended | 5% | 2.1M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 3 Feb 2026 | Artisan Partners Asset Management Inc. | 13G | 5.2% | 2.2M |
| 14 Nov 2025 | RA Capital Management, L.P. | 13G amended | 0% | 0 |
| 12 Nov 2025 | Artisan Partners Asset Management Inc. | 13G amended | 4.3% | 1.8M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 4.1M | +0.75% | 6.1 |
| 30 Sep 2026 | 4.1M | +2.82% | 4.63 |
| 15 Sep 2026 | 4.0M | +2.58% | 5.52 |
| 31 Aug 2026 | 3.9M | -9.02% | 4.63 |
| 14 Aug 2026 | 4.3M | +5.02% | 4.52 |
| 31 Jul 2026 | 4.1M | +5.59% | 4.04 |
| 15 Jul 2026 | 3.8M | -30.33% | 2.78 |
| 30 Jun 2026 | 5.5M | +31.91% | 3.44 |
Funds that hold it
From each fund's latest Form 13F.
186 funds held it at 30 Jun 2026: 95 added and 35 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 5,790,408 | $27.9M | +2,603,316 |
| Millennium Management LLC | 3,030,287 | $14.6M | +970,828 |
| No Street GP LP | 2,055,000 | $9.9M | +55,000 |
| Nomura Holdings Inc. | 2,000,060 | $9.6M | 0 |
| D. E. Shaw & Co., Inc. | 1,985,215 | $9.6M | +25,483 |
| Vanguard Capital Management LLC | 1,675,582 | $8.1M | -17,353 |
| AQR Capital Management LLC | 1,533,826 | $7.4M | +897,697 |
| Acadian Asset Management LLC | 1,501,180 | $7.2M | +482,053 |
| Federated Hermes, Inc. | 1,201,195 | $5.8M | +120,483 |
| Two Sigma Investments, LP | 1,147,048 | $5.5M | -153,212 |
Peers
Companies in the same industry.
- Cooper Companies, Inc. (COO): revenue $4.2B, market value $11.3B
- Bausch & Lomb Corp. (BLCO): revenue $5.4B, market value $7.1B
- Warby Parker Inc. (WRBY): revenue $911.6M, market value $2.7B
- National Vision Holdings, Inc. (EYE): revenue $2.0B, market value $1.3B
- Staar Surgical Co. (STAA): revenue $339.6M, market value $1.2B